AcquisitionsAug 13, 2026, 04:26 PM
Ensysce Acquires Cy Biopharma, Secures $77M Funding, Reports Q2 Loss
AI Summary
Ensysce Biosciences announced the completion of its acquisition of Cy Biopharma, adding CY200, an Orphan Drug-designated candidate for Complex Regional Pain Syndrome (CRPS), as its new lead pipeline asset. The acquisition was accompanied by new funding of up to $77 million, significantly extending the company's cash runway into late 2027. For the second quarter ended June 30, 2026, Ensysce reported a net loss of $2.6 million and increased R&D expenses to $2.5 million, reflecting increased clinical activity.
Key Highlights
- Completed acquisition of Cy Biopharma on August 6, 2026, adding CY200 as lead pipeline asset.
- Secured up to $77 million in new funding, extending cash runway into late 2027.
- CY200, an Orphan Drug-designated candidate for Complex Regional Pain Syndrome (CRPS), will advance to Phase 2 trial.
- Q2 2026 net loss attributable to common stockholders was $2.6 million.
- Research & Development expenses increased to $2.5 million in Q2 2026 from $1.9 million in Q2 2025.
- Cash and cash equivalents were $0.7 million as of June 30, 2026, increasing to $31 million net post-acquisition.
- Received third year of NIDA grant funding, completing the $15.1 million award for PF614-MPAR.
- Strengthened MPAR® intellectual property with a new patent in Taiwan extending through 2042.
Price Impact
More from ENSC